retatrutide phase 2 trial type 2 diabetes weight loss Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide Results: 28.3% Weight Loss

Red or pink urine May indicate blood in urine (hematuria) or food/medication pigments

Drug Interactions and Cardiovascular Effects Common Drug Interactions with GLP-1 Medications When using GLP-1 receptor agonists to improve cardiovascular health, its crucial to understand how these medications interact with others

Triple agonist Retatrutide vs dual agonist Tirzepatide: which works better

The House-version of the annual defense policy bill, which passed out of the chamber this summer, includes a provision that would require the defense secretary to develop a strategy to align the Pentagons obesity-related programs with the classification of obesity as a medically accepted disease